Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions

James Olen Armitage, D. D. Weisenburger, M. Hutchins, D. F. Moravec, M. Dowling, S. Sorensen, J. Mailliard, J. Okerbloom, P. S. Johnson, D. Howe

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Fifty-one patients with diffuse large-cell lymphoma (DLCL) were treated with a six-drug combination chemotherapy regimen including cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone. The patients were restaged after three cycles of therapy, and restaging was repeated at 2-month intervals in patients who had persistent disease. Responding patients received two cycles of therapy after documentation of complete remission (CR). With all patients considered evaluable, 73% of the patients achieved a CR. Twenty-six of the 37 CRs (70%) achieved remission in the first three treatment cycles. The durability of remission in the rapidly responding patients was significantly better than for patients who required five cycles to achieve CR (80% v 40% at 2 years, P = .02) despite the latter patients having received two more cycles of therapy. Rapidly responding patients with DLCL do not require prolonged therapy and have a better prognosis than patients achieving a CR more slowly.

Original languageEnglish (US)
Pages (from-to)160-164
Number of pages5
JournalJournal of Clinical Oncology
Volume4
Issue number2
DOIs
StatePublished - Jan 1 1986

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Procarbazine
Therapeutics
Bleomycin
Vincristine
Drug Combinations
Prednisone
Combination Drug Therapy
Documentation
Doxorubicin
Cyclophosphamide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions. / Armitage, James Olen; Weisenburger, D. D.; Hutchins, M.; Moravec, D. F.; Dowling, M.; Sorensen, S.; Mailliard, J.; Okerbloom, J.; Johnson, P. S.; Howe, D.

In: Journal of Clinical Oncology, Vol. 4, No. 2, 01.01.1986, p. 160-164.

Research output: Contribution to journalArticle

Armitage, JO, Weisenburger, DD, Hutchins, M, Moravec, DF, Dowling, M, Sorensen, S, Mailliard, J, Okerbloom, J, Johnson, PS & Howe, D 1986, 'Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions', Journal of Clinical Oncology, vol. 4, no. 2, pp. 160-164. https://doi.org/10.1200/JCO.1986.4.2.160
Armitage, James Olen ; Weisenburger, D. D. ; Hutchins, M. ; Moravec, D. F. ; Dowling, M. ; Sorensen, S. ; Mailliard, J. ; Okerbloom, J. ; Johnson, P. S. ; Howe, D. / Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 2. pp. 160-164.
@article{15aeebf1dfc741deb916c67afa5c0318,
title = "Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions",
abstract = "Fifty-one patients with diffuse large-cell lymphoma (DLCL) were treated with a six-drug combination chemotherapy regimen including cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone. The patients were restaged after three cycles of therapy, and restaging was repeated at 2-month intervals in patients who had persistent disease. Responding patients received two cycles of therapy after documentation of complete remission (CR). With all patients considered evaluable, 73{\%} of the patients achieved a CR. Twenty-six of the 37 CRs (70{\%}) achieved remission in the first three treatment cycles. The durability of remission in the rapidly responding patients was significantly better than for patients who required five cycles to achieve CR (80{\%} v 40{\%} at 2 years, P = .02) despite the latter patients having received two more cycles of therapy. Rapidly responding patients with DLCL do not require prolonged therapy and have a better prognosis than patients achieving a CR more slowly.",
author = "Armitage, {James Olen} and Weisenburger, {D. D.} and M. Hutchins and Moravec, {D. F.} and M. Dowling and S. Sorensen and J. Mailliard and J. Okerbloom and Johnson, {P. S.} and D. Howe",
year = "1986",
month = "1",
day = "1",
doi = "10.1200/JCO.1986.4.2.160",
language = "English (US)",
volume = "4",
pages = "160--164",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions

AU - Armitage, James Olen

AU - Weisenburger, D. D.

AU - Hutchins, M.

AU - Moravec, D. F.

AU - Dowling, M.

AU - Sorensen, S.

AU - Mailliard, J.

AU - Okerbloom, J.

AU - Johnson, P. S.

AU - Howe, D.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Fifty-one patients with diffuse large-cell lymphoma (DLCL) were treated with a six-drug combination chemotherapy regimen including cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone. The patients were restaged after three cycles of therapy, and restaging was repeated at 2-month intervals in patients who had persistent disease. Responding patients received two cycles of therapy after documentation of complete remission (CR). With all patients considered evaluable, 73% of the patients achieved a CR. Twenty-six of the 37 CRs (70%) achieved remission in the first three treatment cycles. The durability of remission in the rapidly responding patients was significantly better than for patients who required five cycles to achieve CR (80% v 40% at 2 years, P = .02) despite the latter patients having received two more cycles of therapy. Rapidly responding patients with DLCL do not require prolonged therapy and have a better prognosis than patients achieving a CR more slowly.

AB - Fifty-one patients with diffuse large-cell lymphoma (DLCL) were treated with a six-drug combination chemotherapy regimen including cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone. The patients were restaged after three cycles of therapy, and restaging was repeated at 2-month intervals in patients who had persistent disease. Responding patients received two cycles of therapy after documentation of complete remission (CR). With all patients considered evaluable, 73% of the patients achieved a CR. Twenty-six of the 37 CRs (70%) achieved remission in the first three treatment cycles. The durability of remission in the rapidly responding patients was significantly better than for patients who required five cycles to achieve CR (80% v 40% at 2 years, P = .02) despite the latter patients having received two more cycles of therapy. Rapidly responding patients with DLCL do not require prolonged therapy and have a better prognosis than patients achieving a CR more slowly.

UR - http://www.scopus.com/inward/record.url?scp=0022600848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022600848&partnerID=8YFLogxK

U2 - 10.1200/JCO.1986.4.2.160

DO - 10.1200/JCO.1986.4.2.160

M3 - Article

C2 - 2418167

AN - SCOPUS:0022600848

VL - 4

SP - 160

EP - 164

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -